The study involves a review of the electronic medical records of patients infected with SARSCoV- 2. The research data set has removed most, but not all protected health information (for example: actual dates of infection were included as needed for analysis, but would be considered PHI). The dataset is also considered property of Hackensack Meridian Health and not owned by the investigators. Therefore, for both reasons, the dataset cannot be made openly available. However, upon request we are willing to share portions of the data for appropriate review. Requests can be made through the corresponding author or directly to representatives of Hackensack Meridian Health (Dr Ihor Sawczuk, Chief Research Officer HMH; Email: <Ihor.Sawczuk@hackensackmeridian.org>). We have included in the Supporting Information the statistical output that may assist interested readers in understanding the data more fully and could be utilized to assist in independent confirmation.

Introduction {#sec001}
============

The global pandemic caused by a novel coronavirus \[severe acute respiratory syndrome (SARS)-CoV-2\] and its disease, COVID-19, has led to infection in over 15.8 million individuals and more than 640,000 deaths as of July 25, 2020 \[[@pone.0237693.ref001], [@pone.0237693.ref002]\]. As there are no approved treatments, management of COVID-19 is largely supportive \[[@pone.0237693.ref003], [@pone.0237693.ref004]\].

One empirical treatment for COVID-19 which has received attention is hydroxychloroquine, an antimalarial drug repurposed in recognition of its anti-inflammatory properties in the treatment of autoimmune conditions. Hydroxychloroquine and its analogue, chloroquine, demonstrate suppression of SARS-CoV-2 replication in vitro, with hydroxychloroquine demonstrating greater potency \[[@pone.0237693.ref005], [@pone.0237693.ref006]\]. Studies from the original SARS-CoV virus suggest a mechanism of action involving impairment of the terminal glycosylation of angiotensin converting enzyme 2 (ACE2), inhibition of SARS-CoV viral entry, and rapid elevation of endosomal pH that prevents endosome-mediated viral entry \[[@pone.0237693.ref007]--[@pone.0237693.ref010]\]. The immunomodulatory effects are thought to be due to the accumulation of the drug in lymphocytes and macrophages leading to reduction of proinflammatory cytokines, including type I interferons, tumor necrosis factor alpha, and interleukin-6 \[[@pone.0237693.ref009]\]. Other anti-inflammatory effects may be related to inhibition of signaling pathways \[[@pone.0237693.ref011]\].

Several early small clinical reports have shown conflicting evidence regarding the efficacy of hydroxychloroquine in COVID-19 \[[@pone.0237693.ref012], [@pone.0237693.ref013]\]. Subsequently, an observational cohort study of 1376 hospitalized patients from a New York hospital using propensity modeling found no significant association between hydroxychloroquine use and intubation or death (hazard ratio, 1.04, 95% confidence interval, 0.82 to 1.32) \[[@pone.0237693.ref014]\]. A second observational cohort study of 1438 hospitalized patients throughout the New York metropolitan region also found a lack of survival association with hydroxychloroquine with or without concomitant azithromycin (HR 1.35 and 1.08 respectively) \[[@pone.0237693.ref015]\]. A recently reported randomized Brazilian trial enrolling 504 hospitalized SARS-CoV-2 confirmed patients with mild-to-moderate disease (defined as not requiring significant supplemental oxygen support) found that a 7-day course of hydroxychloroquine either with azithromycin or alone did not result in better clinical outcomes as measured by a seven-level ordinal scale at 15 days \[[@pone.0237693.ref016]\].

As the clinical course of COVID-19 progresses, patients enter a hyperinflammatory phase with dysregulation of adaptive immune responses and a cytokine storm with elevation in plasma levels of pro-inflammatory cytokines including interleukins (IL) 2,6, 7, and 10, granulocyte-colony stimulating factor (G-CSF), interferon-gamma-inducible protein-10 (IFN-gamma, IL-10), and tumor necrosis factor alpha (TNF-alpha). This cytokine storm results in a pro-thrombotic milieu, cardiomyopathy, and ultimately multi-organ failure \[[@pone.0237693.ref017], [@pone.0237693.ref018]\]. Tocilizumab, a monoclonal antibody against membrane bound IL-6 receptor inhibiting binding of soluble IL-6 and subsequent signal transduction, has been proposed as a therapeutic candidate for impeding cytokine storm \[[@pone.0237693.ref019]\]. Small single institution series have suggested benefit among severely ill patients \[[@pone.0237693.ref020], [@pone.0237693.ref021]\]. Preliminary results from a press release for the French CORIMUNO-TOCI trial (NCT04331808), an open-label randomized trial of hospitalized patients with COVID-19 (n = 129), noted a reduction in the proportion of participants who died or needed ventilation in the tocilizumab group, although full results of the trial have not yet been released \[[@pone.0237693.ref022]\]. An Italian observational study involving 544 COVID-19 patients (with 16% requiring mechanical ventilator support) reported that tocilizumab treatment was associated with a reduced risk of subsequent invasive mechanical ventilation or death \[[@pone.0237693.ref023]\]. A Michigan USA observational study also noted an associated reduction in mortality among intubated COVID-19 patients \[[@pone.0237693.ref024]\].

In the absence of RCTs, observational studies may provide useful early insights into effective treatment strategies \[[@pone.0237693.ref025], [@pone.0237693.ref026]\]. However in an observational study, treatment allocations are based upon physician judgement, rather than random assignment, increasing the risk of bias and not accounting for known and unknown risk factors. Thus, causal inferences on effectiveness of treatments are challenging, but confounding effects can be partially mitigated via statistical methods \[[@pone.0237693.ref027], [@pone.0237693.ref028]\].

Understanding these limitations, but with the urgency for evaluating potential therapeutic approaches during the current COVID-19 pandemic, we established an observational database within a 13-hospital network spanning New Jersey using an integrated electronic health record (EHR) system (EPIC; Verona, WI). In this observational cohort study we report our survival outcomes with hydroxychloroquine and tocilizumab among hospitalized patients with COVID-19.

Methods {#sec002}
=======

Study design and cohort selection {#sec003}
---------------------------------

This retrospective, observational, multicenter cohort within the Hackensack Meridian Health network (HMH) used EHR-derived data to study hospitalized COVID-19 patient outcomes. Our primary objective was to analyze the effect of hydroxychloroquine in hospitalized patients. A secondary, exploratory objective was to investigate the effect of tocilizumab in the ICU population.

Patients were included in the database based on the following inclusion and exclusion criteria: 1) Positive SARS-CoV-2 diagnosis by reverse-transcriptase polymerase chain reaction, 2) Hospitalized within the time frame of March 1, 2020 until May 5, 2020, 3) Non-pregnant, 4) Not on a randomized clinical trial, and 5) Did not die during first day of hospitalization, and 5) Were not discharged to home within 24 hours ([Fig 1](#pone.0237693.g001){ref-type="fig"}).

![Cohort selection flow diagram.\
Flow Diagram of patient sampling strategy of hospitalized COVID-19 patients in Hackensack Meridian Health network. \*Convenience sampling was performed when assigning patients to our data team, and sampling bias is possible. 3325 of the 3438 (97%) available records were abstracted. \*\*Follow-up until final study cut-off date of May 5, 2020. \*\*\* 53 patients who received toci did not have sufficient data (date of administration) to analyze Tocilizumab (toci); Hydroxychloroquine (HCQ).](pone.0237693.g001){#pone.0237693.g001}

Hackensack Meridian Health Institutional Review Board approved this study on March 27, 2020 under study \# Pro2020-0342. Waiver of consent and HIPAA authorization was granted as this retrospective research was a non-interventional protocol utilizing electronic health records to abstract data. No patients were contacted for this study. Protected health information was not made available except to investigators. De-identified information was provided to statisticians. The study period was March 1, 2020 until May 5, 2020.

Data sources and baseline variables {#sec004}
-----------------------------------

We collected data from HMH's EHR (Epic) which is utilized throughout the network. Hospitalized patients throughout HMH were flagged by the EHR if SARS-CoV-2 testing was positive. These EHR-generated reports served as our eligible cohort to sample. Demographic, clinical characteristics, treatments, and outcomes were manually abstracted by research nurses and physicians from the John Theurer Cancer Center at Hackensack University Medical Center. Assigning patients to our data team occurred in real-time, and not randomized. To reduce sampling bias, we abstracted 3325 of the 3438 (97%) possible hospitalized patients by April 22, 2020 (with follow up until May 5, 2020), and performed stratification as discussed in our analytic approach. Data abstracted by the team was entered using REDCap (Research Electronic Data Capture) hosted at HMH \[[@pone.0237693.ref029], [@pone.0237693.ref030]\]. Data abstraction occurred daily from March 28, 2020 until May 5, 2020. Quality control was performed by physicians (AI, SLG) overseeing nurse or physician abstraction.

Demographic information was collected by an electronic face sheet, with gender, race or ethnicity self-reported. Academic centers were defined as quaternary referral centers with accredited residency, fellowship, and medical student programs. Nursing home or rehabilitation patients, if diagnosed prior to hospital admission, were defined as ambulatory patients. Comorbidities were defined as diagnosed prior to hospitalized for COVID-19. History of hypertension, diabetes, chronic lung disease (COPD or asthma), hypertension, cancer, coronary artery disease, cerebrovascular disease, renal failure, and rheumatologic disorder were abstracted from provider notes or medical history sections found within the EHR. If not listed in the patient's record, the comorbidity was recorded as absent.

Presenting clinical data was abstracted from thorough review of unstructured notes as well as structured data. Hospital readmissions were counted as the same admission, with baseline data used from the initial hospitalization. If multiple positive or indeterminate results were found in a patient's record for SARS-CoV-2, the first initial positive test was used as the date of diagnosis.

Exposures {#sec005}
---------

For the effect of hydroxychloroquine, we separated patients into 4 different groups-- 1) Hydroxychloroquine, 2) Hydroxychloroquine in combination with Azithromycin, 3) Azithromycin alone, and 4) neither drug. Exposure to hydroxychloroquine or azithromycin was defined as documentation of drug administration in the EHR. Dosing, duration, and timing in relation to symptom onset and admission were also collected. If no evidence of administration of drug was found, this was recorded as not having received the drug.

For tocilizumab, exposure was defined as receipt of the drug within the ICU setting as found in the EHR. If no date of administration was found, this was labeled as insufficient missing data for analysis. If no evidence of administration of the drug was found, this was recorded as not having received the drug.

Outcome measures {#sec006}
----------------

The primary outcome measurement was death with follow-up through May 5, 2020. Mortality was identified on chart review by a provider note announcing time of death or if the EHR labeled the patient as deceased. As death certificates were not readily available, cause of death was identified using the EHR by identifying the most immediate cause(s) documented \[[@pone.0237693.ref031]\]. Respiratory cause of death included any hypoxic condition related to COVID-19. Cardiac cause of death included cardiac arrest, myocardial infarction, or arrhythmias. Infectious cause of death included bacterial sepsis or secondary infections not including COVID-19. Other cause of death included multi-organ failure as well as alternative causes. Follow-up occurred until the study cut-off date of May 5.

Adverse drug events related to hydroxychloroquine were also described, including discontinuation due to arrhythmia or QT prolongation. This was obtained by provider documentation as well as EKG reports within the EHR.

Statistical analyses {#sec007}
--------------------

The statistical plan is available in the ([S1 Appendix](#pone.0237693.s001){ref-type="supplementary-material"}). Descriptive analyses of baseline characteristics by hydroxychloroquine exposure were performed using chi-square tests for categorical variables. Dose, frequency, timing, and duration of treatment were also summarized.

We used propensity-score stratification for the remaining statistical analyses \[[@pone.0237693.ref032], [@pone.0237693.ref033]\]. We fit a logistic regression model to the probability of being assigned to the experimental arm (tocilizumab, hydroxychloroquine, or hydroxychloroquine plus azithromycin) compared with the control population (not assigned to the respective treatment). Patients are stratified into propensity-score quintiles and these strata are used to adjust treatment effects in a proportional hazards model.

The model for selecting factors to be included in propensity scores was a two-stage backward selection approach. We evaluated each of the factors as univariate predictors with factors having p-value less than 0.10 included for further consideration. We removed factors sequentially and one at a time from the multivariate model if their p-values were less than 0.50, with largest p-values considered first. We fit the final propensity-scores model using multivariate logistic regression of the selected factors. We then stratified the propensity scores for the entire population into quintiles and used these quintiles as an ordinal (4-degree-of-freedom) variable to adjust the relative treatment comparison in a proportional hazards model (see [S2 Appendix](#pone.0237693.s002){ref-type="supplementary-material"}, for output).

We evaluated the following factors for all propensity-score models: gender, coronary disease, stroke, heart failure, arrhythmia, African American, COPD, renal failure, rheumatologic disorder, inflammatory bowel disease, advanced liver disease, age, diabetes mellitus, insulin use prior to hospitalization, asthma, HIV/hepatitis, any cancer, and log ferritin. The final propensity-score model for hydroxychloroquine included the first 15 of these factors. That for hydroxychloroquine plus azithromycin included the first 15 of these factors plus cancer. That for tocilizumab included age, gender, COPD, and renal failure.

Tocilizumab was assigned preferentially for patients in the ICU. Tocilizumab patients included in our analyses received their first dose of the drug in the ICU. Control patients were those who were admitted to the ICU and who never received tocilizumab either before or after admission to the ICU. The start time for analysis was the day of admission to the ICU. Hydroxychloroquine and hydroxychloroquine plus azithromycin were evaluated from day of hospital admission, whether initially in the ICU or not. The control population consisted of patients who never received the respective treatment.

We also sought to address the factorial nature of treatment with combination hydroxychloroquine and azithromycin. Propensity scores are based on predicting particular an individual therapy and so do not naturally generalize to a factorial setting. For these analyses we averaged the two propensity scores calculated separately for hydroxychloroquine and hydroxychloroquine plus azithromycin. We then stratified into propensity quintiles based on that average and proceeded as indicated above. The raw results of our proportional hazards analyses adjusting for propensity scores is provided ([S2 Appendix](#pone.0237693.s002){ref-type="supplementary-material"}).

Patients still alive and in the hospital were censored as of May 5, 2020. Patients who had been discharged from the hospital were censored as of day 36 following hospital admission.

We provide hazard ratios of treatment in comparison with control together with corresponding p-values and confidence intervals based on Wald tests. We show the unadjusted survival data using Kaplan-Meier plots from which we identify 30-day mortality for each treatment. Statistical calculations used JMP^®^ Pro 15.0.0. Confidence intervals and p-values in this study are descriptive measures of distance between outcomes of treatment groups or distance from hazard ratio 1.00. These measures do not have the same inferential interpretations that are possible for primary end point analyses of RCTs.

Results {#sec008}
=======

Unadjusted baseline characteristics of hospitalized patients {#sec009}
------------------------------------------------------------

There were 3,438 patients flagged in our EHR with positive COVID19 infection within the 13-hosptial network spanning New Jersey, and data was abstracted on 3,325 (97%). 2512 hospitalized patients met inclusion criteria for this study ([Fig 1](#pone.0237693.g001){ref-type="fig"}). As indicated in [Table 1](#pone.0237693.t001){ref-type="table"}, the median age of the cohort was 64 years (IQR 52--76) with a male predominance (62%). Nursing home and rehabilitation patients comprised 16% of the cohort. Co-morbidities were common with 55% having hypertension, 41% obesity (BMI ≥30), 32% diabetes, 16% coronary arterial disease, 15% COPD/asthma, 12% cancer, and 31% having 3 or more chronic conditions.

10.1371/journal.pone.0237693.t001

###### Unadjusted baseline characteristics of hospitalized COVID-19 patients.

![](pone.0237693.t001){#pone.0237693.t001g}

                                                                  [All (n = 2512)]{.ul}   [No HCQ (n = 598)]{.ul}   [HCQ]{.ul}[\*](#t001fn001){ref-type="table-fn"}[(n = 1914)]{.ul}   [P-value]{.ul}
  --------------------------------------------------------------- ----------------------- ------------------------- ------------------------------------------------------------------ ----------------
  [**Demographics, n (%)**]{.ul}                                                                                                                                                       
  **Age Median (Iqr)**                                            64 (52--76)             66 (52--80)               64 (53--75)                                                        0.011
  **Age Distribution**                                                                                                                                                                 
  \[0,10\]                                                        16                      12 (75%)                  4 (25%)                                                            \<.001
  \[10,20\]                                                       8                       3 (38%)                   5 (62%)                                                            
  \[20,30\]                                                       54                      20 (37%)                  34 (63%)                                                           
  \[30,40\]                                                       153                     42 (27%)                  111 (73%)                                                          
  \[40,50\]                                                       314                     71 (23%)                  243 (77%)                                                          
  \[50,60\]                                                       490                     90 (18%)                  400 (82%)                                                          
  \[60,70\]                                                       570                     117 (21%)                 453 (79%)                                                          
  \[70,80\]                                                       477                     106 (22%)                 371 (78%)                                                          
  \[80,90\]                                                       332                     97 (29%)                  235 (71%)                                                          
  \[90,100\]                                                      98                      40 (41%)                  58 (59%)                                                           
  **Gender**                                                                                                                                                                           0.09
  Female                                                          945                     242 (26%)                 703 (74%)                                                          
  Male                                                            1,565                   354 (22%)                 1,211 (78%)                                                        
  Missing                                                         2                       2 (100%)                  0 (0%)                                                             
  **Race/Ethnicity**                                                                                                                                                                   \<.001
  African American                                                285                     80 (28%)                  205 (72%)                                                          
  Asian                                                           105                     10 (10%)                  95 (90%)                                                           
  Caucasian                                                       1,308                   339 (26%)                 969(74%)                                                           
  Hispanic                                                        483                     89 (18%)                  394 (82%)                                                          
  Other[\*](#t001fn001){ref-type="table-fn"}                      255                     55 (22%)                  200 (78%)                                                          
  Missing                                                         76                      25 (33%)                  51 (67%)                                                           
  **Nursing Home/Rehab**[\*\*](#t001fn002){ref-type="table-fn"}                                                                                                                        \<.001
  No                                                              2,082                   447 (21%)                 1,635 (79%)                                                        
  Yes                                                             396                     143 (36%)                 253 (64%)                                                          
  Missing                                                         34                      8 (24%)                   26 (76%)                                                           
  **Academic vs. Community**                                                                                                                                                           0.24
  Academic                                                        777                     197 (25%)                 580 (75%)                                                          
  Community                                                       1,735                   401(23%)                  1,334 (77%)                                                        
  **Smoking History**                                                                                                                                                                  0.69
  Current                                                         77                      20 (26%)                  57 (74%)                                                           
  Former                                                          448                     112 (25%)                 336 (75%)                                                          
  Neither (Non-Smoker)                                            1,620                   378 (23%)                 1,242 (77%)                                                        
  Missing                                                         367                     77 (21%)                  290 (79%)                                                          
  [**Comorbidities, n (%)**]{.ul}                                                                                                                                                      
  **Comorbidity Count**                                                                                                                                                                0.001
  0                                                               444                     134 (30%)                 310 (70%)                                                          
  1                                                               665                     142 (21%)                 523 (79%)                                                          
  2                                                               634                     132 (20%)                 502 (80%)                                                          
  *≥*3                                                            769                     190 (24%)                 579 (76%)                                                          
  **Diabetes**                                                                                                                                                                         0.09
  No                                                              1,699                   422 (25%)                 1,277 (75%)                                                        
  Yes                                                             813                     176 (22%)                 637 (78%)                                                          
  **COPD/asthma**                                                                                                                                                                      0.80
  No                                                              2,136                   506 (24%)                 1,630 (76%)                                                        
  Yes                                                             376                     92(24%)                   284 (76%)                                                          
  **Hypertension**                                                                                                                                                                     0.67
  No                                                              1,126                   263 (23%)                 863 (77%)                                                          
  Yes                                                             1,386                   335 (24%)                 1,051 (76%)                                                        
  **Coronary Disease**                                                                                                                                                                 0.04
  No                                                              2,114                   487 (23%)                 1,627 (77%)                                                        
  Yes                                                             398                     111 (28%)                 287 (72%)                                                          
  **Cerebrovascular Disease**                                                                                                                                                          0.002
  No                                                              2,389                   554 (23%)                 1,835 (77%)                                                        
  Yes                                                             123                     44(36%)                   79(64%)                                                            
  **Cancer**                                                                                                                                                                           0.86
  No                                                              2,221                   527 (24%)                 1,694 (76%)                                                        
  Yes                                                             291                     71(24%)                   220 (76%)                                                          
  **Renal Failure**                                                                                                                                                                    0.93
  No                                                              2,325                   553 (25%)                 1,772 (75%)                                                        
  Yes                                                             187                     45 (24%)                  142 (76%)                                                          
  **Rheumatologic Disorder**                                                                                                                                                           0.04
  No                                                              2,437                   588(24%)                  1,849 (76%)                                                        
  Yes                                                             75                      10 (13%)                  65 (87%)                                                           
  **Obesity (BMI**[**\>**]{.ul}**30)**                                                                                                                                                 \<0.001
  No                                                              1630                    427 (26%)                 1203 (74%)                                                         
  Yes                                                             882                     171 (19%)                 711 (81%)                                                          
  [**Presenting Symptoms, n (%)**]{.ul}                                                                                                                                                
  **Fever**                                                                                                                                                                            \<0.001
  No                                                              704                     214 (30%)                 490 (70%)                                                          
  Yes                                                             1,808                   384 (21%)                 1,424 (79%)                                                        
  **Cough**                                                                                                                                                                            \<0.001
  No                                                              805                     260 (32%)                 545 (68%)                                                          
  Yes                                                             1,707                   338 (20%)                 1,369 (80%)                                                        
  **Shortness of Breath**                                                                                                                                                              \<0.001
  No                                                              778                     279 (36%)                 499 (64%)                                                          
  Yes                                                             1,734                   319 (18%)                 1,415 (82%)                                                        
  **GI**[\*\*\*](#t001fn003){ref-type="table-fn"}                                                                                                                                      0.33
  No                                                              1,940                   471 (24%)                 1,469 (76%)                                                        
  Yes                                                             572                     127 (22%)                 445 (78%)                                                          
  **Altered Mental State**                                                                                                                                                             0.007
  No                                                              2,210                   507(23%)                  1,703 (77%)                                                        
  Yes                                                             302                     91(30%)                   211 (70%)                                                          
  [**Disease severity, n (%)**]{.ul}                                                                                                                                                   
  **Oxygenation** *\<* **94%**                                                                                                                                                         \<0.001
  No                                                              1,370                   403 (29%)                 967 (71%)                                                          
  Yes                                                             1,107                   178 (16%)                 929 (84%)                                                          
  Missing                                                         35                      17 (49%)                  18 (51%)                                                           
  **Ferritin \>1500 ng/mL**                                                                                                                                                            0.62
  No                                                              1313                    214 (16%)                 1099 (84%)                                                         
  Yes                                                             400                     70 (18%)                  330 (82%)                                                          
  Missing                                                         799                     314 (39%)                 485 (61%)                                                          
  **D-Dimer \> 1 mcg/mL**                                                                                                                                                              0.30
  No                                                              872                     131 (15%)                 741 (85%)                                                          
  Yes                                                             172                     20 (12%)                  152 (88%)                                                          
  Missing                                                         1468                    447(30%)                  1021 (70%)                                                         
  **ICU Admission**[\*\*\*\*](#t001fn004){ref-type="table-fn"}                                                      0.88                                                               
  Admitted                                                        150                     37 (25%)                  113 (75%)                                                          
  Not Admitted                                                    2,362                   561 (24%)                 1,801 (76%)                                                        

\*Hydroxychloroquine (HCQ) administration of at least one dose, and at any point during hospitalization.

\*\*Includes multi-racial, and not specified in other choices

\*\*\*Admitted from a nursing home or rehabilitation facility

\*\*\*\* Includes nausea, vomiting, diarrhea, or other Gastrointestinal complaint obtained from medical record.

\*\*\*\*\*Admission to ICU on first day of hospitalization, as defined by chart review of medical record.

At the time of hospital presentation, fever was present in 72%, 69% with dyspnea, 68% with cough, 23% gastrointestinal complaints and 12% had altered mental status. The median time from self-reported onset of symptoms to hospitalization was 5 days (IQR 3--7). 611 (24%) patients required intensive care unit support during their hospitalization, of which 150 patients were admitted to the ICU within the first day. Oxygen saturation below 94% was identified in 44%. When measured and recorded in the electronic health record, inflammatory markers were elevated with serum ferritin \>1500 ng/mL in 23% and d-dimer \>1 mcg/mL in 16% of patients.

Treatment with hydroxychloroquine {#sec010}
---------------------------------

In this non-randomized observational cohort 1914 hospitalized patients (76%) received at least one dose of hydroxychloroquine during the study timeframe (23% as single agent and 77% in combination with azithromycin) ([Fig 1](#pone.0237693.g001){ref-type="fig"}). Dosing and duration was at prescribers' discretion. The majority of patients received 800 mg on day 1, and 400 mg on day 2--5 (80%, n = 1533), followed by 200 mg TID (4%, n = 71) and other (15%, n = 299), and missing dosing information (1%, n = 11). Median duration of hydroxychloroquine was 5 days (IQR 4--5). The median days of symptoms before hydroxychloroquine administration was 5 (IQR 2--9), and median days in hospital before first dose 1 was 1 (IQR 0--2).

Patients receiving hydroxychloroquine at any time during their hospitalization were younger, less likely to live in a nursing home, but presented later in their clinical course (5 days vs 3 days of symptoms prior to hospital admission) with more symptomatic disease (higher incidences of fever, cough, dyspnea, and lower oxygen saturation) ([Table 1](#pone.0237693.t001){ref-type="table"}). After the United States Food and Drug Administration Emergency Use Authorization on March 28, 2020, prescriptions of hydroxychloroquine in our cohort temporally increased \[569 (30%) prior to March 28 compared to 1314 (68%) post announcement, 42 (2%) dates missing\] \[[@pone.0237693.ref034]\].

Discontinuation of hydroxychloroquine due to prolongation of QTc or arrhythmias was recorded in the electronic health records in 76 (4%) and 33 (2%) patients. During the entire hospital course, arrhythmias were noted in 101 (5%) hydroxychloroquine patients, compared to 22 (4%) in the non-hydroxychloroquine cohort. Cardiomyopathy was described in 20 (1%) treated patients compared to 7 (1%) patients without hydroxychloroquine.

Survival outcomes and hydroxychloroquine therapy {#sec011}
------------------------------------------------

Among 2512 hospitalized patients with COVID-19 there have been 547 deaths (22%), 1539 (61%) discharges and 426 (17%) remain hospitalized as of the study cut-off date. In the entire cohort, causes of death included 319 (58%) respiratory, 108 (20%) cardiac, 42 (8%) other, 41 (7%) infectious, and 37 (7%) other. Within the hydroxychloroquine treated cohort, 89 of 432 (21%) of deaths were attributed to cardiac causes, compared to 19 of 115 (16%) deaths in the non-hydroxychloroquine cohort.

As shown in [Table 2](#pone.0237693.t002){ref-type="table"}, using propensity modeling as described above, there was no significant association between survival and any use of hydroxychloroquine during the hospitalization (HR, 0.99 \[95% CI, 0.80--1.22\]), hydroxychloroquine alone (HR, 1.02 \[95% CI, 0.83--1.27\]), or hydroxychloroquine in combination with azithromycin (HR, 0.98 \[95% CI, 0.75--1.28\]). The unadjusted 30-day mortality for patients receiving hydroxychloroquine alone, azithromycin alone, the combination or neither drug was 25%, 20%, 18%, and 20%, respectively ([Fig 2](#pone.0237693.g002){ref-type="fig"}).

![Unadjusted association of treatment with hydroxychloroquine on overall survival among hospitalized COVID-19 patients.\
Unadjusted Kaplan-Meier estimates of survival by treatment allocation to hydroxychloroquine (HCQ), azithromycin (AZI), both, or neither. Patients at risk at admission, day 10, day 20, and day 30 are shown. Patients still alive and in the hospital were censored as of May 5, 2020. Patients who had been discharged from the hospital were censored as of day 36 following hospital admission. 30-day mortality rates are shown for each treatment.](pone.0237693.g002){#pone.0237693.g002}

10.1371/journal.pone.0237693.t002

###### Propensity-score adjusted hazard ratios, confidence intervals.

![](pone.0237693.t002){#pone.0237693.t002g}

                                                          HR     95% conf. interval   P-value   30-day mortality rate                     
  ------------------------------------------------------- ------ -------------------- --------- ----------------------- ----------------- ----------------
  Any HCQ in hospital                                     0.99   0.80                 1.22      0.92                    0.20              0.20
  HCQ+AZI in hospital                                     0.98   0.75                 1.28      0.89                    0.18              0.20
  Factorial main effects and interaction of HCQ and AZI                                                                                   
  HCQ main effect                                         1.02   0.83                 1.27      0.83                    0.25 (HCQ only)   0.20 (Neither)
  AZI main effect                                         0.89   0.72                 1.10      0.28                    0.20 (AZI only)   0.20 (Neither)
  Interaction                                                                                   0.091                   0.18 (Both)       0.20 (Neither)
  Tocilizumab therapy in the Intensive Care Unit                                                                                          
  Toci in ICU                                             0.76   0.57                 1.00      0.053                   0.46              0.56

Toci Tocilizumab; HCQ hydroxychloroquine; AZI azithromycin. Toci in ICU includes all patients whose first dose of tocilizumab was in the ICU or controls who were admitted to the ICU and known to not have received tocilizumab during their hospital stay. "In hospital" includes all patients who received the drug at any time during their stay in the hospital. "Main effect" is the estimated benefit of the drug whether added to the other drug or not. A drug given "only" means not with the other drug. 30-day mortality rates are estimated using the corresponding Kaplan-Meier survival curve at 30 days (See Figs [2](#pone.0237693.g002){ref-type="fig"} and [3](#pone.0237693.g003){ref-type="fig"}).

![Unadjusted association of treatment with tocilizumab on overall survival among hospitalized ICU COVID-19 patients.\
Unadjusted Kaplan-Meier estimates of survival by treatment allocation to tocilizumab (toci) or no toci. Patients at risk at admission, day 10, day 20, and day 30 are shown. Patients still alive and in the hospital were censored as of May 5, 2020. Patients who had been discharged from the hospital were censored as of day 36 following hospital admission. 30-day unadjusted mortality with and without tocilizumab is 46% versus 56%.](pone.0237693.g003){#pone.0237693.g003}

Exploratory analysis on tocilizumab therapy {#sec012}
-------------------------------------------

198 (8%) patients received tocilizumab therapy during their hospitalization. [Table 3](#pone.0237693.t003){ref-type="table"} shows baseline characteristics. 11 patients received their first dose prior to admission to the ICU and 53 patients had unknown timing or insufficient data. Thus 134 patients with documentation of their first dose of tocilizumab within an ICU setting represented the exploratory treatment cohort. 413 patients in the ICU never received tocilizumab as of May 5, 2020 and serve as the control cohort. Tocilizumab was administered as a single dose in 104 (78%), with the majority receiving 400 mg (96%), followed by 800 mg (1%), 8 mg/kg (1%), 4 mg/kg (1%), and missing dosing (1%). Secondary bacteremia occurred in 44 of the 413 (11%) patients in the non-treated group, compared to 18/134 (13%) in the treated group. Secondary pneumonia occurred in 25 of the 413 (6%) patients in the non-treated group, compared to 12 of the 134 (9%) in the treated group. As shown in [Table 2](#pone.0237693.t002){ref-type="table"}, in the analysis using propensity modeling, there was a trend association between survival and treatment with tocilizumab within the ICU setting (HR, 0.76 \[95% CI, 0.57--1.00\]). The unadjusted 30-day mortality favored tocilizumab (46% versus 56%) ([Fig 3](#pone.0237693.g003){ref-type="fig"}).

10.1371/journal.pone.0237693.t003

###### Unadjusted baseline characteristics of evaluable ICU patients receiving tocilizumab.

![](pone.0237693.t003){#pone.0237693.t003g}

                                                                    [All Patients (n = 547)]{.ul}   [No Toci (n = 413)]{.ul}   [Toci]{.ul}[\*](#t003fn001){ref-type="table-fn"} [(n = 134)]{.ul}   [P-value]{.ul}
  ----------------------------------------------------------------- ------------------------------- -------------------------- ------------------------------------------------------------------- ----------------
  [**Demographics, n (%)**]{.ul}                                                                                                                                                                   
  **Age Median (Iqr)**                                              67 (58--76)                     69 (58--77)                62 (53--70)                                                         \<0.0001
  **Age Distribution, n (%)**                                                                                                                                                                      0.0008
  \[0,10\]                                                          1                               1 (100%)                   0 (0%)                                                              
  \[10,20\]                                                         4                               4 (100%)                   0 (0%)                                                              
  \[20,30\]                                                         9                               5 (56%)                    4 (44%)                                                             
  \[30,40\]                                                         19                              11 (58%)                   8 (42%)                                                             
  \[40,50\]                                                         42                              29 (69%)                   13 (31%)                                                            
  \[50,60\]                                                         101                             66 (65%)                   35 (35%)                                                            
  \[60,70\]                                                         155                             114 (74%)                  41 (26%)                                                            
  \[70,80\]                                                         133                             108 (81%)                  25 (19%)                                                            
  \[80,90\]                                                         72                              64 (89%)                   8 (11%)                                                             
  \[90,100\]                                                        11                              11 (100%)                  0 (0%)                                                              
  **Gender**                                                                                                                                                                                       0.016
  Female                                                            191                             156 (82%)                  35 (18%)                                                            
  Male                                                              356                             257 (72%)                  99 (28%)                                                            
  Missing                                                           0                                                                                                                              
  **Race/Ethnicity**[\*\*](#t003fn002){ref-type="table-fn"}                                                                                                                                        0.19
  African American                                                  47                              35 (74%)                   12 (26%)                                                            
  Asian                                                             29                              17 (59%)                   12 (41%)                                                            
  Caucasian                                                         316                             239 (76%)                  77 (24%)                                                            
  Hispanic                                                          95                              74 (78%)                   21 (22%)                                                            
  Other                                                             43                              36 (84%)                   7 (16%)                                                             
  Missing                                                           17                              12 (71%)                   5 (29%)                                                             
  **Nursing Home/Rehab**[\*\*\*](#t003fn003){ref-type="table-fn"}                                                                                                                                  \<0.0001
  No                                                                471                             344 (73%)                  127 (27%)                                                           
  Yes                                                               64                              60 (94%)                   4 (6%)                                                              
  Missing                                                           12                              9 (75%)                    3 (25%)                                                             
  **Academic vs. Community**                                                                                                                                                                       \<0.0001
  Academic                                                          177                             159 (90%)                  18 (10%)                                                            
  Community                                                         370                             254 (69%)                  116 (31%)                                                           
  **Smoking History**                                                                                                                                                                              0.26
  Current                                                           18                              13 (72%)                   5 (28%)                                                             
  Former                                                            92                              74 (80%)                   18 (20%)                                                            
  Neither (Non-Smoker)                                              326                             235 (72%)                  91 (28%)                                                            
  Missing                                                           111                             91 (82%)                   20 (18%)                                                            
  [**Comorbidities, n (%)**]{.ul}                                                                                                                                                                  
  **Comorbidity Count**                                                                                                                                                                            0.003
  0                                                                 70                              51 (73%)                   19 (27%)                                                            
  1                                                                 144                             94 (65%)                   50 (35%)                                                            
  2                                                                 141                             118 (84%)                  23 (16%)                                                            
  *≥*3                                                              192                             150 (78%)                  42 (22%)                                                            
  **Diabetes**                                                                                                                                                                                     0.61
  No                                                                343                             256 (75%)                  87 (25%)                                                            
  Yes                                                               204                             157 (77%)                  47 (23%)                                                            
  **COPD/asthma**                                                                                                                                                                                  0.69
  No                                                                458                             344 (75%)                  114 (25%)                                                           
  Yes                                                               89                              69 (78%)                   20 (22%)                                                            
  **Hypertension**                                                                                                                                                                                 0.04
  No                                                                207                             146 (71%)                  61 (29%)                                                            
  Yes                                                               340                             267 (79%)                  73 (21%)                                                            
  **Coronary Disease**                                                                                                                                                                             0.80
  No                                                                447                             336 (75%)                  111 (25%)                                                           
  Yes                                                               100                             77 (77%)                   23 (23%)                                                            
  **Cerebrovascular Disease**                                                                                                                                                                      0.35
  No                                                                521                             391 (75%)                  130 (25%)                                                           
  Yes                                                               26                              22 (85%)                   4 (15%)                                                             
  **Cancer**                                                                                                                                                                                       0.18
  No                                                                479                             357 (75%)                  122 (25%)                                                           
  Yes                                                               68                              56 (82%)                   12 (18%)                                                            
  **Renal Failure**                                                                                                                                                                                0.097
  No                                                                492                             366 (74%)                  126 (26%)                                                           
  Yes                                                               55                              47 (85%)                   8 (15%)                                                             
  **Rheumatologic Disorder**                                                                                                                                                                       0.59
  No                                                                528                             397 (75%)                  131 (25%)                                                           
  Yes                                                               19                              16 (84%)                   3 (16%)                                                             
  **Obesity (BMI** [**\>**]{.ul}**30)**                                                                                                                                                            
  No                                                                344                             261 (76%)                  83 (24%)                                                            
  Yes                                                               203                             152 (75%)                  51 (25%)                                                            
  [**Presenting Symptoms, n (%)**]{.ul}                                                                                                                                                            
  **Fever**                                                                                                                                                                                        0.011
  No                                                                154                             128 (83%)                  26 (17%)                                                            
  Yes                                                               393                             285 (73%)                  108 (27%)                                                           
  **Cough**                                                                                                                                                                                        0.018
  No                                                                173                             142 (82%)                  31 (18%)                                                            
  Yes                                                               374                             271 (72%)                  103 (28%)                                                           
  **Shortness of Breath**                                                                                                                                                                          0.042
  No                                                                144                             118 (82%)                  26 (18%)                                                            
  Yes                                                               403                             295 (73%)                  108 (27%)                                                           
  **GI**[\*\*\*\*](#t003fn004){ref-type="table-fn"}                                                                                                                                                0.33
  No                                                                434                             332 (76%)                  102 (24%)                                                           
  Yes                                                               113                             81 (72%)                   32 (28%)                                                            
  **Altered Mental State**                                                                                                                                                                         0.89
  No                                                                461                             347 (75%)                  114 (25%)                                                           
  Yes                                                               86                              66 (77%)                   20 (23%)                                                            
  [**Disease severity, n (%)**]{.ul}                                                                                                                                                               
  **Oxygenation** *\<* **94**                                                                                                                                                                      0.69
  No                                                                229                             175 (76%)                  54 (24%)                                                            
  Yes                                                               317                             237 (75%)                  80 (25%)                                                            
  Missing                                                           1                               1 (100%)                   0 (0%)                                                              
  **ICU Admission**[\*\*\*\*\*](#t003fn005){ref-type="table-fn"}                                                                                                                                   0.36
  Admitted                                                          137                             108 (79%)                  29 (21%)                                                            
  Not Admitted                                                      410                             305 (74%)                  105 (26%)                                                           
  [**Treatments, n (%)**]{.ul}                                                                                                                                                                     
  **Steroids**                                                                                                                                                                                     0.60
  No                                                                195                             150 (77%)                  45 (23%)                                                            
  Yes                                                               352                             263 (75%)                  89 (25%)                                                            
  **Hydroxychloroquine**                                                                                                                                                                           0.004
  No                                                                61                              55 (90%)                   6 (10%)                                                             
  Yes                                                               486                             358 (74%)                  128 (26%)                                                           
  **Azithromycin**                                                                                                                                                                                 \<0.0001
  No                                                                128                             120 (94%)                  8 (6%)                                                              
  Yes                                                               419                             293 (70%)                  126 (30%)                                                           
  **Hydroxychloroquine+azithromycin**                                                                                                                                                              \<0.0001
  No                                                                156                             145 (90%)                  14 (10%)                                                            
  Yes                                                               391                             268 (69%)                  123 (31%)                                                           

\*Tocilizumab (toci) administration of at least one dose, and if given after entering the ICU. Those who were given toci prior to ICU (n = 11) were excluded. Those who had insufficient dates of administration or ICU admission were also excluded (n = 53).

\*\*Includes multi-racial, and not specified in other choices.

\*\*\*Admitted from a nursing home or rehabilitation facility.

\*\*\*\* Includes nausea, vomiting, diarrhea, or other Gastrointestinal complaint obtained from medical record.

\*\*\*\*\*Admission to ICU on first day of hospitalization, as defined by chart review of medical record.

Discussion {#sec013}
==========

This retrospective observational cohort study of 2512 hospitalized COVID-19 patients within a 13- hospital network did not find the empirical use of hydroxychloroquine with or without co-treatment with azithromycin to be associated with a reduction in mortality (adjusted HR, 0.99 for any hydroxychloroquine during hospitalization \[95% CI, 0.80--1.22\]). Our multi-center findings confirm the recent observational studies from New York \[[@pone.0237693.ref014], [@pone.0237693.ref015]\]. Our results are also in agreement with the results of a recent randomized controlled study that enrolled patients with only mild-to-moderate disease, a cohort with less severe than our study \[[@pone.0237693.ref016]\]. Collectively these studies do not support the routine use of hydroxychloroquine outside a clinical trial. Furthermore, none of the reported observational studies have addressed the role of hydroxychloroquine among individuals with minimally symptomatic disease in the pre-hospital setting.

Unlike randomized controlled trials, observational studies have inherent biases in patient allocations that cannot be fully adjusted for during statistical analyses. Although we utilized propensity modeling to mitigate known imbalances it is possible that unmeasured confounding factors may still be important. For example, in our series we observed a change in the prescribing patterns of hydroxychloroquine during the study timeframe. Similarly dosing and timing of hydroxychloroquine varied throughout the 13-hospital network. These factors (dosing, schedules, and changes in treatment patterns over time) are difficult to quantify in large observational studies. Nonetheless, our primary analysis is concordant with the other recent studies.

A potentially clinically important finding from an exploratory analysis revealed a favorable association between tocilizumab administration and survival among COVID-19 patients requiring ICU support. Our study represents one of the largest report of tocilizumab during this pandemic but is subject to all of the concerns of observational studies. However, if confirmed by ongoing randomized clinical trials, tocilizumab would represent the first successful therapy to reduce mortality.

Limitations {#sec014}
-----------

Multiple ongoing RCT's will ultimately determine the efficacy of hydroxychloroquine and tocilizumab in COVID-19. This observational study has limitations. First, observational studies cannot draw causal inferences given inherent known and unknown confounders. We attempted to adjust for known confounders using our propensity model approach. Second, misclassification is possible as we performed manual abstraction of EHR data. Third, hydroxychloroquine is a drug that likely has a therapeutic window that requires appropriate dosing, duration, and timing of administration \[[@pone.0237693.ref035]\]. We acknowledge our results should be interpreted with caution as significant heterogeneity existed within these factors, although a majority of our patients received the same dose, completed 5 days of treatment, and were given the drug within 24 hours of hospitalization. Fourth, low sample size limited our exploratory tocilizumab analysis. Fifth, our study focused on patients in New Jersey, limiting the applicability to other geographic regions, although the state's population is diverse, and the network included 13-hospitals (both academic and community) all with differing COVID-19 treatment protocols. Lastly, we acknowledge the possibility of sampling bias as we collected data from a convenience sample in attempts to conduct the investigation quickly during this pandemic.

Conclusions {#sec015}
-----------

This observational cohort study from a multi-hospital system spanning New Jersey, when taken together with other studies, does not support the routine (off label and outside of clinical trial) use of hydroxychloroquine to reduce mortality among hospitalized COVID-19 patients. We cannot comment about the efficacy of this agent in the pre-hospital setting. Our exploratory review of IL-6 blockade with tocilizumab among ICU patients is encouraging and warrants further study. Common concerns regarding the limitations of observational studies should be applied until results of randomized trials are available.
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